Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of its shares of common stock for up to an aggregate amount of $125…
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…
Davis Polk Advises ViewRay, Inc. on a $50 Million Direct Registered Equity Offering
Davis Polk advised ViewRay, Inc. in a direct registered offering of 8,382,643 shares of ViewRay’s common stock for proceeds to ViewRay of approximately $50 million. ViewRay’s common stock…
Davis Polk Advises Auris Medical Holding AG on Its Registered Offering of Common Shares and Equity Line of Financing
Davis Polk advised Auris Medical Holding AG in connection with the SEC-registered offering of $1.5 million of its common shares to Lincoln Park Capital Fund, LLC. The common shares are…
Flexion Therapeutics, Inc. $122.4 Million Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4,800,000 shares of common stock by Flexion Therapeutics, Inc. The…
Hologic, Inc. $350 Million Senior Notes Offering
Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Hologic, Inc. of $350 million aggregate principal amount of its 4.375% senior…
Deciphera Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offerings of Common Stock and Warrants to Purchase Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with an $80.4 million offering of 22,275,000 shares of common stock and warrants to purchase 8,910,000 shares of common stock, which…
Juno Therapeutics, Inc. $288 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $288 million public offering of common stock by Juno…